Sells pharmaceutical products in India, generating Rs 2,519.65 crore in revenue in FY26, up 10.4% year-on-year with net profit of Rs 722.43 crore. The product range includes the hormone-based menopause therapy Premarin Vaginal Cream, an imported product that contributes less than 1% of revenue. Q1 FY27 revenue was Rs 653.17 crore, up 8.3% year-on-year, with net profit of Rs 204.47 crore. Employee costs are the largest operating expense at 14.6% of revenue, with materials at 12.3% and other operating expenses at 14.4%. Capital expenditure was 1.0% of revenue in FY26, and the company has no subsidiaries, has operated for 75 years, and declared a Rs 75 per share dividend for the year. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical products, Premarin Vaginal Cream (1%). Established, asset-light Indian pharmaceutical company that imports and sells products; no subsidiaries.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 |
| EBITDA (ex other income) | 836 | 842 | 643 | 913 | 855 |
| margin % | 32.0 | 34.7 | 29.3 | 40.0 | 33.9 |
| Owners' profit | 613 | 624 | 551 | 768 | 722 |
| EPS, as reported (₹) | 133.89 | 136.38 | 120.51 | 167.79 | 157.92 |
| ROE % · ROCE % | 21.4 · 25.7 | 19.5 · 25.0 | 15.3 · 20.7 | 18.2 · 23.6 | 17.2 · 22.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 667 | 356 | 257 | 660 | 968 |
| Capex | (15) | (65) | (19) | (28) | (25) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 589 | 538 | 592 | 603 | 1,245 | 645 | 629 | 653 |
| Profit before tax | 215 | 172 | 426 | 260 | 515 | 192 | 269 | 277 |
| Net profit | 158 | 128 | 331 | 192 | 381 | 142 | 200 | 204 |
| EPS (₹) | 34.61 | 27.89 | 72.34 | 41.91 | 83.23 | 31.01 | 43.68 | 44.69 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Pfizer to discontinue Minipress XL, receives Rs 131 Cr from parent | business updates | medium | — | — |
| 4 Aug 2026 · Pfizer informs about newspaper ad on physical shares re-lodgement window | compliance | minimal | — | — |
| 29 Jul 2026 · Pfizer AGM 2026: All resolutions passed; Rs 75 final dividend confirmed | board shareholder meetings | low | — | — |
| 28 Jul 2026 · Pfizer 75th AGM: Rs 75 dividend declared, FY26 results adopted | board shareholder meetings | low | — | — |
| 28 Jul 2026 · Pfizer Q1 FY27 net profit at Rs 204 cr, revenue up 8% YoY | results | high | — | — |
| 27 Jul 2026 · Pfizer CFO Amit Agarwal resigns, effective October 8, 2026 | management changes | high | — | — |
| 20 Jul 2026 · Pfizer board meeting on July 28, 2026 to consider Q1 FY27 financial results | results | low | — | — |
| 17 Jul 2026 · Pfizer clarifies temporary Premarin Cream supply disruption, under 1pct of revenue | business updates | medium | — | — |
| 17 Jul 2026 · NSE seeks clarification on Premarin cream suspension news | compliance | medium | — | — |
| 10 Jul 2026 · Compliance certificate under SEBI Regulation 74(5) for Q1 FY27 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 20.0 | 28.9 | 57 of 169 | 67% |
| P/B | 4.4 | 3.3 | 104 of 163 | 36% |
| ROCE | 22.7 | 10.8 | 22 of 183 | 89% |
| ROE | 17.2 | 10.4 | 36 of 171 | 79% |
| Debt / Equity | 0.0 | 0.1 | 42 of 171 | 76% |
| EBITDA margin | 44.8 | 17.5 | 6 of 165 | 97% |
| Revenue growth | 8.3 | 16.3 | 100 of 161 | 38% |
| Profit growth | 6.6 | 30.9 | 104 of 158 | 34% |
| Market cap | 18575 | 839 | 30 of 182 | 84% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
